Article

Nvidia and Eli Lilly will jointly invest $1 billion over five years to establish a research lab in the San Francisco Bay Area, utilizing Nvidia's Vera Rubin AI chips. This announcement coincides with the JPMorgan Healthcare Conference and follows Lilly's plans to build a supercomputer with over 1,000 Nvidia Grace Blackwell AI chips.

The investment aims to enhance drug development by integrating Nvidia's AI models and software into Eli Lilly's pharmaceutical processes. The location of the new facility will be disclosed in March, where researchers from both companies will collaborate on generating data for AI model training in biotechnology. Nvidia has also introduced updated AI models to ensure the practical synthesis of AI-designed drugs.